Beactica Announces Fragment-Based Drug Discovery Agreement

UPPSALA, Sweden, April 27, 2011 - Beactica, the leading Swedish fragment-based drug discovery company,
today announced that it has entered into an agreement with Janssen Research &
Development, a division of Janssen Pharmaceutica NV. Under the agreement,
Beactica will use its proprietary drug discovery platform, Sprint(TM), to
generate small-molecule lead compounds against undisclosed targets of
therapeutic interest to Janssen. Financial terms of the agreement were not
disclosed.

"We are pleased to work with Janssen and look forward to utilising
Beactica's platform to support the progress of one of their prioritized
programmes" said Beactica CEO, Dr Per Källblad. "Fragment-based approaches to
drug discovery are creating new pathways towards small-molecule leads of
high-quality and Beactica has worked hard to win a reputation for being at
the cutting-edge of advances".

Janssen is the fourth global top-20 pharmaceutical company to enter into
an agreement with Beactica in the past 18 months.

About Beactica

Beactica AB is a specialist drug discovery company, utilising its
proprietary methodologies to evaluate the biophysical interaction of
molecules in order to generate novel therapeutics. The Company offers
expertise and services in the area of surface plasmon resonance (SPR)
biosensor-based small molecule interaction analysis and partnerships for
fragment-based lead generation using its proprietary Sprint(TM) platform.
Founded in 2006 based on research carried out at Uppsala University and
first-hand experience from the drug discovery industry, Beactica has
established a robust reputation as the leader in SPR-based small molecule
drug discovery. As well as providing services and building collaborations
with external companies, Beactica is progressing its own drug discovery
programmes. The company has its headquarter in Uppsala, Sweden. For more
information, please visit www.beactica.com.

For additional information please contact Dr Per Källblad, Beactica CEO,
+46-18-56-08-80.

.